Topical tretinoin treatment for burning mouth syndrome: a pilot study

Quintessence Int. 2022 Oct 21;53(10):860-867. doi: 10.3290/j.qi.b3315031.

Abstract

Objectives: Burning mouth syndrome is an intraoral chronic pain condition characterized by a moderate to severe sensation of burning from the oral mucosa. No clinical signs are found and there is no efficient treatment.

Method and materials: This pilot study included 10 women that were resistant to other previous treatments or noncompliant to systemic medications. Patients were asked to apply tretinoin gel 0.05% on their tongues twice daily for 14 days. Treatment effectiveness was assessed by completing a pre-study psychologic questionnaire and recording a daily wellbeing and pain log.

Results: Significant pain-score decrease in 50% of the patients (delta numerical rating score -3.15 ± 3.02, P value = .005) was recorded. This finding was in concordance with the verbal statements including major quality-of-life improvement (P value = .05), without any treatment positive or negative predictive factors.

Conclusions: Topical tretinoin exhibits potential efficacy in patients with treatment resistant burning mouth syndrome and may also be used as a primary treatment modality.

Keywords: burning mouth syndrome; retinoids; tretinoin; vitamin A.

MeSH terms

  • Administration, Topical
  • Burning Mouth Syndrome* / chemically induced
  • Burning Mouth Syndrome* / drug therapy
  • Chronic Disease
  • Chronic Pain*
  • Female
  • Humans
  • Pilot Projects
  • Treatment Outcome
  • Tretinoin / adverse effects
  • Tretinoin / therapeutic use

Substances

  • Tretinoin